C
와이바이오로직스
338840KOSDAQ42.5 / 100
Reference Date: 2026-10-23
Financial Score9.0 / 40
News Sentiment12.5 / 25
Momentum11.0 / 20
Disclosure10.0 / 15
AI Analysis: ROE is below the industry average, PBR raises overvaluation concerns. Rose 5.3% over the past month, with no recent news.
Company InformationBased on 2025 Annual Report
Business Overview
WaiBioLogics is a biopharmaceutical company developing advanced antibody-based therapies, including immune checkpoint inhibitors, ADCs, and bispecific antibodies, leveraging its proprietary discovery platform. Key pipelines include YBL-006, AR166, AR169, and AR170, with revenue generated through technology licensing and contract research services.
Number of Employees
58people
Average Salary
60.4M KRW
Score Calculation Basis
Detailed Financial Score
PER
—Industry Average 15.004.0Point
PBR
5.04Industry Average 1.200.0Point
4.2x industry avg (risky)
ROE
-186.97Industry Average 8.000.0Point
Well below industry avg
Debt Ratio
105.13Industry Average 100.002.0Point
Higher than industry avg (caution)
Trend 2023~20253.0 / 10 points
Revenue Growth Rate
2.0 / 3
Avg ▲8.1% (2-year basis)
Operating Profit Growth Rate
1.0 / 3
Avg ▲3.5% (2-year basis)
ROE Trend
0.0 / 4
Avg ROE -111.6% (declining, 3yr)
Detailed News Sentiment
0 totalPositive 0Neutral 0Negative 0
Detailed Momentum
52-week position1.0Point
Near 52w low (6%, downtrend)
Current 8,710Won52-week high 35,60052-week low 6,830
1-month return4.0Point
1m +5.32% (slight rise)
Volume trend6.0Point
Volume surge
Detailed Disclosure
7 totalPositive 0Neutral 7Negative 0
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-20
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-15
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-15
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-14
- Neutral임원ㆍ주요주주특정증권등소유상황보고서2026-10-14